Argenx : An excellent Q3 2024 beating expectations. Target price raised to € 580
>Forecasts beaten for sales and EBIT - Q3 sales were up by 74% y-o-y and 34% q-o-q to $ 573m (US $ 492m, Japan $ 24m, EMEA $ 46m and $ 11m supply in China), reflecting both strong demand for products (i.e. Vyvgart and Vyvgart Hytrulo) and excellent commercial execution. Note that this quarter includes CIPD sales for the first time. The group provides no information on the breakdown by indication but indicates that the launch of this new indication “got off to an impr...Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.